What biomarker testing is recommended for metastatic Lung Cancer

Biomarker Testing for Metastatic Lung Cancer

Biomarker testing is a critical part of treating metastatic non-small cell lung cancer (NSCLC). These tests identify specific genetic mutations or protein changes in your cancer cells that help your oncologist choose the most effective treatment for YOUR particular cancer.

Key Biomarkers Tested in Metastatic NSCLC

According to NCCN Guidelines for Patients: Metastatic Non-Small Cell Lung Cancer, the following biomarkers are routinely evaluated:

Primary Biomarkers (Usually Tested First)

1. PD-L1 Expression

   • Measures a protein on cancer cells that helps them hide from the immune system
   • Results guide whether immunotherapy (checkpoint inhibitors) will be effective
   • Reported as a percentage (0%, 1-49%, 50%+)

2. EGFR Mutations

   • Found in about 15-20% of NSCLC cases
   • If present, targeted therapies (like erlotinib or gefitinib) are often very effective
   • Multiple types of EGFR mutations exist, each with different treatment implications

3. ALK Rearrangement

   • A chromosomal change found in 3-5% of NSCLC
   • Responds well to ALK inhibitors (targeted drugs)
   • Tested via fluorescence in situ hybridization (FISH) or immunohistochemistry (IHC)

4. ROS1 Rearrangement

   • Similar to ALK, found in 1-2% of cases
   • Also responds to specific targeted therapies
   • Often tested alongside ALK

Additional Biomarkers (Often Tested)

1. KRAS Mutations

   • Present in 25-30% of NSCLC
   • Historically had limited treatment options, but newer targeted therapies are emerging
   • Important for prognosis and treatment planning

2. BRAF Mutations

   • Found in 1-3% of cases
   • Can be treated with targeted combination therapies
   • Requires specific testing to identify

3. MET Exon 14 Skipping

   • Present in 3-4% of NSCLC
   • Responds to MET inhibitors
   • Important to identify as it changes treatment approach

4. NTRK Fusions

   • Rare but important to identify
   • Responds to NTRK inhibitors (FDA-approved for multiple cancer types)

5. Tumor Mutational Burden (TMB)

   • Measures the total number of mutations in cancer cells
   • High TMB may predict better response to immunotherapy
   • Increasingly used in treatment decisions

How Testing Works

Sample Type: Usually a small piece of tumor tissue from a biopsy or surgery, though blood-based testing (liquid biopsy) is becoming more common

Testing Methods:

• Immunohistochemistry (IHC) - Uses stains to visualize proteins
• Fluorescence In Situ Hybridization (FISH) - Identifies chromosomal changes
• Next-Generation Sequencing (NGS) - Analyzes DNA to find multiple mutations at once
• Liquid Biopsy - Blood test that detects cancer DNA circulating in your bloodstream

Why This Matters for Your Treatment

The results of these biomarker tests directly influence which treatments your oncologist will recommend:

• Targeted therapy (drugs designed to attack specific mutations) often works better and has fewer side effects than traditional chemotherapy for patients with certain biomarkers
• Immunotherapy effectiveness depends partly on PD-L1 levels and other factors
• Combination approaches may be recommended based on your specific biomarker profile

Questions to Ask Your Oncology Team

1. Which biomarkers have been tested on my tumor, and what were the results?
2. Are there any biomarkers that haven't been tested yet that you recommend testing?
3. How do my specific biomarker results influence the treatment options you're recommending?
4. If my initial biomarkers don't show targetable mutations, what's the treatment approach?
5. Can I get a copy of my complete biomarker testing report to keep in my records?

Important Note

Biomarker testing recommendations continue to evolve as new treatments become available. Your oncologist will determine which tests are most appropriate for your specific situation and may recommend additional testing based on your individual case.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.